| CAS NO: | 300816-11-9 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 300816-11-9 |
| 化学名 | N-hydroxy-1,3-dioxo-1H-benz[de]isoquinoline-2(3H)-butanamide |
| Canonical SMILES | O=C(C1=CC=CC2=CC=CC3=C12)N(CCCC(NO)=O)C3=O |
| 分子式 | C16H14N2O4 |
| 分子量 | 298.3 |
| 溶解度 | ≤2mg/ml in DMSO;2mg/ml in dimethyl formamide |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Nullscript is an HDAC inhibitor. Histone deacetylase inhibitors (HDIs) have been used in psychiatry and neurology as mood stabilizers and anti-epileptics, such as valproic acid. Recently, HDIs are being studied as a mitigator or treatment for neurodegenerative diseases. Moreover, there has been an effort to develop HDIs for cancer therapy. In vitro: Nullscript, a close analog of scriptaid, was found to be inactive in transcriptional facilitation at corresponding concentrations, which confirmed a minimal requirement for the length of the linker chain expected for this class of HDAC inhibitors. In addition, nullscript was not able to induce the p6SBE-luc reporter construct, which was identified from the library using ChemFinder by its structural similarity to scriptaid [1]. In vivo: A standard in vivo model of cardiac I/RWe was utilized to examine the in vivo consequences of HDAC inhibition in the intact heart. Results showed that the treatment with scriptaid led to a nearly identical effect when compared to nullscript, with a 46.8% reduction in infarct size. Such results strongly suggested that in murine models, HDACIs could reverse the induction of ischemia-induced HDAC activity and reduced myocardial infarct size by more than 50% [2]. Clinical trial: So far, no clinical study has been conducted. References: |
m.cnreagent.com